pSivida Corp. (NASDAQ:PSDV) was up 2.4% on Monday . The company traded as high as $3.94 and last traded at $3.91, with a volume of 57,321 shares trading hands. The stock had previously closed at $3.82.

Separately, FBR & Co reiterated a “buy” rating and issued a $7.00 price objective (up previously from $6.00) on shares of pSivida Corp. in a research note on Thursday, May 12th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $7.00.

The company’s market capitalization is $134.30 million. The company has a 50 day moving average of $3.25 and a 200-day moving average of $3.10.

pSivida Corp. (NASDAQ:PSDV) last posted its earnings results on Thursday, May 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.05. On average, equities analysts forecast that pSivida Corp. will post ($0.62) EPS for the current fiscal year.

pSivida Corp. is a biotechnology company, which is engaged in the development of sustained-release drug-delivery products for treating eye diseases. The Company offers products for treatment of back-of-the-eye diseases. The Company’s lead development product, Medidur is used for posterior of the eye (posterior uveitis).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.